Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart failure: symptomatic treatment versus prognostic modification].

J S Cardoso1

  • 1Unidade de Investigação e Desenvolvimento Cardiovascular do Porto, Faculdade de Medicina do Porto, Hospital de S. João.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|March 25, 2000
PubMed
Summary

Heart failure treatment focuses on improving prognosis by targeting neurohormonal systems, not just symptoms. Current therapies like ACE inhibitors and beta-blockers aim to counteract these detrimental regulatory systems for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic approach of central sleep apnea in heart failure - the role of adaptive servo-ventilation. A statement of the Portuguese society of pulmonology and the Portuguese sleep association.

Pulmonology·2022
Same author

Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

[Dynamics of heart transplantation lists and anticipated needs].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2001
Same author

[Interaction between antiplatelet agents and angiotensin-converting enzyme inhibitors].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2001
Same author

Treating diastolic heart failure: the role of beta-blockers.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·1999
Same author

Cardiac involvement in human immunodeficiency virus infection.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·1999

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Context:

  • Heart failure prognosis is linked to left ventricular dysfunction and regulatory system activation.
  • Patient symptoms stem from hemodynamic and skeletal muscle issues, often not improving with symptom-relief drugs.
  • Current therapeutic focus is shifting from hemodynamic improvement to influencing prognosis via neurohormonal antagonism.

Purpose:

  • To explore the relationship between heart failure prognosis, left ventricular dysfunction, and regulatory system activation.
  • To highlight the limitations of symptom-focused pharmacological interventions in improving heart failure prognosis.
  • To identify future therapeutic challenges in antagonizing neurohormonal systems for better heart failure outcomes.

Summary:

  • Heart failure prognosis depends on left ventricular dysfunction and activated neurohormonal systems, while symptoms arise from hemodynamic and muscle disturbances.

Related Experiment Videos

  • Symptomatic relief in heart failure does not always correlate with improved prognosis due to the disconnect between symptoms and underlying disease progression.
  • Antagonizing neurohormonal and regulatory systems represents the primary future challenge for improving heart failure prognosis, moving beyond purely hemodynamic management.

    • Impact:

    • Identifies key therapeutic targets for improving heart failure prognosis beyond symptom management.
    • Highlights the importance of neurohormonal antagonism in heart failure treatment strategies.
    • Provides a foundation for developing novel therapies aimed at modifying the long-term course of heart failure.